Cart

Three characteristics are essential for achieving success in Biotech investing: (1) Pipeline diversification. Too much concentration on a single drug subjects investors to potential single day loss of > 40 to 50%; (2) Drug class (mechanism of action) diversification. Too much concentration on pursuing a single, new way to treat a disease jeopardizes a company's survival should the drug class proves to be ineffective; and (3) Company diversification. Since most Biotech success or failure depends on 1 to 2 drugs, making huge bet in any single company exposes investors to an unfavorable risk/reward ratio. The Revere Biotech Pipeline Risk Report addresses all the above issues and more by periodically identifying companies that have

• At least two Phase 3/NDA/BLA filed drug candidates
• One or more drug candidates utilizing a mechanism of action already approved by the FDA
• One or more drug candidates facing two or fewer alternative drugs with the same mechanism of action for the same indication
• An established strategic partnership with one or more blue-chip biopharmaceutical companies
• Market cap between $50 Million and $1 Billion

Using Revere's patented classification system, this report makes available to investors a portfolio of Biotech stocks that address all 3 diversification characteristics mentioned above, thus tilting the odds of winning in their favor.